A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants
Latest Information Update: 26 Dec 2023
Price :
$35 *
At a glance
- Drugs Elasomeran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Moderna Therapeutics
- 19 Dec 2023 Status changed from active, no longer recruiting to completed.
- 06 Sep 2023 According to a Moderna, Inc. media release, clinical trial effectiveness data of Moderna's COVID-19 vaccine against BA.2.86 have been shared with regulators and submitted for peer review publication.
- 06 Sep 2023 Results published in a Moderna, Inc. media release.